Robert H Habib1, Kamellia R Dimitrova2, Sanaa A Badour3, Maroun B Yammine3, Abdul-Karim M El-Hage-Sleiman3, Darryl M Hoffman2, Charles M Geller2, Thomas A Schwann4, Robert F Tranbaugh5. 1. Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; Outcomes Research Unit, American University of Beirut, Beirut, Lebanon; Vascular Medicine Program, American University of Beirut, Beirut, Lebanon. Electronic address: rh106@aub.edu.lb. 2. Department of Cardiovascular Surgery, Mount Sinai Beth Israel Medical Center, New York, New York. 3. Outcomes Research Unit, American University of Beirut, Beirut, Lebanon. 4. Department of Surgery, University of Toledo College of Medicine, Toledo, Ohio. 5. Department of Cardiovascular Surgery, Mount Sinai Beth Israel Medical Center, New York, New York. Electronic address: rtranbau@chpnet.org.
Abstract
BACKGROUND: Treatment of multivessel coronary artery disease with traditional single-arterial coronary artery bypass graft (SA-CABG) has been associated with superior intermediate-term survival and reintervention compared with percutaneous coronary intervention (PCI) using either bare-metal stents (BMS) or drug-eluting stents (DES). OBJECTIVES: This study sought to investigate longer-term outcomes including the potential added advantage of multiarterial coronary artery bypass graft (MA-CABG). METHODS: We studied 8,402 single-institution, primary revascularization, multivessel coronary artery disease patients: 2,207 BMS-PCI (age 66.6 ± 11.9 years); 2,381 DES-PCI (age 65.9 ± 11.7 years); 2,289 SA-CABG (age 69.3 ± 9.0 years); and 1,525 MA-CABG (age 58.3 ± 8.7 years). Patients with myocardial infarction within 24 h, shock, or left main stents were excluded. Kaplan-Meier analysis and Cox regression were used to separately compare 9-year all-cause mortality and unplanned reintervention for BMS-PCI and DES-PCI to respective propensity-matched SA-CABG and MA-CABG cohorts. RESULTS: BMS-PCI was associated with worse survival than SA-CABG, especially from 0 to 7 years (p = 0.015) and to a greater extent than MA-CABG was (9-year follow-up: 76.3% vs. 86.9%; p < 0.001). The surgery-to-BMS-PCI hazard ratios (HR) were as follows: versus SA-CABG, HR: 0.87; and versus MA-CABG, HR: 0.38. DES-PCI showed similar survival to SA-CABG except for a modest 0 to 3 years surgery advantage (HR: 1.06; p = 0.615). Compared with MA-CABG, DES-PCI exhibited worse survival at 5 (86.3% vs. 95.6%) and 9 (82.8% vs. 89.8%) years (HR: 0.45; p <0.001). Reintervention was substantially worse with PCI for all comparisons (all p <0.001). CONCLUSIONS: Multiarterial surgical revascularization, compared with either BMS-PCI or DES-PCI, resulted in substantially enhanced death and reintervention-free survival. Accordingly, MA-CABG represents the optimal therapy for multivessel coronary artery disease and should be enthusiastically adopted by multidisciplinary heart teams as the best evidence-based therapy.
BACKGROUND: Treatment of multivessel coronary artery disease with traditional single-arterial coronary artery bypass graft (SA-CABG) has been associated with superior intermediate-term survival and reintervention compared with percutaneous coronary intervention (PCI) using either bare-metal stents (BMS) or drug-eluting stents (DES). OBJECTIVES: This study sought to investigate longer-term outcomes including the potential added advantage of multiarterial coronary artery bypass graft (MA-CABG). METHODS: We studied 8,402 single-institution, primary revascularization, multivessel coronary artery diseasepatients: 2,207 BMS-PCI (age 66.6 ± 11.9 years); 2,381 DES-PCI (age 65.9 ± 11.7 years); 2,289 SA-CABG (age 69.3 ± 9.0 years); and 1,525 MA-CABG (age 58.3 ± 8.7 years). Patients with myocardial infarction within 24 h, shock, or left main stents were excluded. Kaplan-Meier analysis and Cox regression were used to separately compare 9-year all-cause mortality and unplanned reintervention for BMS-PCI and DES-PCI to respective propensity-matched SA-CABG and MA-CABG cohorts. RESULTS: BMS-PCI was associated with worse survival than SA-CABG, especially from 0 to 7 years (p = 0.015) and to a greater extent than MA-CABG was (9-year follow-up: 76.3% vs. 86.9%; p < 0.001). The surgery-to-BMS-PCI hazard ratios (HR) were as follows: versus SA-CABG, HR: 0.87; and versus MA-CABG, HR: 0.38. DES-PCI showed similar survival to SA-CABG except for a modest 0 to 3 years surgery advantage (HR: 1.06; p = 0.615). Compared with MA-CABG, DES-PCI exhibited worse survival at 5 (86.3% vs. 95.6%) and 9 (82.8% vs. 89.8%) years (HR: 0.45; p <0.001). Reintervention was substantially worse with PCI for all comparisons (all p <0.001). CONCLUSIONS: Multiarterial surgical revascularization, compared with either BMS-PCI or DES-PCI, resulted in substantially enhanced death and reintervention-free survival. Accordingly, MA-CABG represents the optimal therapy for multivessel coronary artery disease and should be enthusiastically adopted by multidisciplinary heart teams as the best evidence-based therapy.
Authors: Robert F Tranbaugh; Kamellia R Dimitrova; Patricia Friedmann; Charles M Geller; Loren J Harris; Paul Stelzer; Bertram Cohen; Darryl M Hoffman Journal: Ann Thorac Surg Date: 2010-10 Impact factor: 4.330
Authors: Patrick W Serruys; Andrew T L Ong; Lex A van Herwerden; J Eduardo Sousa; Adib Jatene; Johannes J R M Bonnier; Jacques P M A Schönberger; Nigel Buller; Robert Bonser; Clemens Disco; Bianca Backx; Paul G Hugenholtz; Brian G Firth; Felix Unger Journal: J Am Coll Cardiol Date: 2005-08-16 Impact factor: 24.094
Authors: Akhil Kapur; Roger J Hall; Iqbal S Malik; Ayesha C Qureshi; Jeremy Butts; Mark de Belder; Andreas Baumbach; Gianni Angelini; Adam de Belder; Keith G Oldroyd; Marcus Flather; Michael Roughton; Petros Nihoyannopoulos; Jens Peder Bagger; Kenneth Morgan; Kevin J Beatt Journal: J Am Coll Cardiol Date: 2010-02-02 Impact factor: 24.094
Authors: Brian F Buxton; William Y Shi; James Tatoulis; John A Fuller; Alexander Rosalion; Philip A Hayward Journal: J Thorac Cardiovasc Surg Date: 2014-07-17 Impact factor: 5.209
Authors: Bruce W Lytle; Eugene H Blackstone; Joseph F Sabik; Penny Houghtaling; Floyd D Loop; Delos M Cosgrove Journal: Ann Thorac Surg Date: 2004-12 Impact factor: 4.330
Authors: Whady Hueb; Neuza Helena Lopes; Bernard J Gersh; Paulo Soares; Luiz A C Machado; Fabio B Jatene; Sergio A Oliveira; Jose A F Ramires Journal: Circulation Date: 2007-03-06 Impact factor: 29.690
Authors: John D Puskas; Adil Sadiq; Thomas A Vassiliades; Patrick D Kilgo; Omar M Lattouf Journal: Ann Thorac Surg Date: 2012-06-06 Impact factor: 4.330
Authors: Thomas A Schwann; Anoar Zacharias; Christopher J Riordan; Samuel J Durham; Aamir S Shah; Robert H Habib Journal: Ann Thorac Surg Date: 2009-07 Impact factor: 4.330
Authors: A Dionne; M Bakloul; C Manlhiot; B W McCrindle; M Hosking; C Houde; D Pepelassis; N Dahdah Journal: Pediatr Cardiol Date: 2016-09-23 Impact factor: 1.655